Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children

Shiragami, Makoto; Mizukami, Akiko; Leeuwenkamp, O. R.; Mrkvan, Tomáš; Delgleize, Emmanuelle; Kurono, Yuichi; Iwata, Satoshi

doi:10.1007/s40121-014-0053-7

Cited by 30 publications

(60 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PHiD-CV 2+1 was predicted to be dominant over PCV13 2+1. This dominance is in line with various other cost-effectiveness analyses, from Malaysia [ 10 ], Japan [ 57 ], the Philippines [ 27 ], Turkey [ 58 ], Europe [ 20 , 59 – 61 ], Canada [ 20 ] and Peru [ 53 ]. However, some studies have predicted the reverse: that PCV13 would be dominant over PHiD-CV (Malaysia and Hong Kong [ 11 ], Colombia [ 62 ], Europe [ 63 ] and Canada [ 64 ]) or more cost-effective than PHiD-CV (Peru [ 65 ]).…”

Section: Discussionsupporting

confidence: 82%

Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia

Wang

Saha²,

Zhang

2017

Cost Eff Resour Alloc

View full text Add to dashboard Cite

BackgroundCurrently, two pediatric pneumococcal conjugate vaccines are available in the private market of Malaysia—13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). This study aimed to evaluate the cost-effectiveness of a universal mass vaccination program with a PHiD-CV 2+1 schedule versus no vaccination or with a PCV13 2+1 schedule in Malaysia.MethodsA published Markov cohort model was adapted to evaluate the epidemiological and economic consequences of programs with no vaccination, a PHiD-CV 2+1 schedule or a PCV13 2+1 schedule over a 10-year time horizon. Disease cases, deaths, direct medical costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were estimated. Locally published epidemiology and cost data were used whenever possible. Vaccine effectiveness and disutility data were based on the best available published data. All data inputs and assumptions were validated by local clinical and health economics experts. Analyses were conducted from the perspective of the Malaysian government for a birth cohort of 508,774. Costs and QALYs were discounted at 3% per annum. One-way and probabilistic sensitivity analyses were performed.ResultsCompared with no vaccination, a PHiD-CV 2+1 program was projected to prevent 1109 invasive pneumococcal disease (IPD), 24,679 pneumonia and 72,940 acute otitis media (AOM) cases and 103 IPD/pneumonia deaths over 10 years, with additional costs and QALYs of United States dollars (USD) 30.9 million and 1084 QALYs, respectively, at an ICER of USD 28,497/QALY. Compared with a PCV13 2+1 program, PHiD-CV 2+1 was projected to result in similar reductions in IPD cases (40 cases more) but significantly fewer AOM cases (30,001 cases less), with cost savings and additional QALYs gained of USD 5.2 million and 116 QALYs, respectively, demonstrating dominance over PCV13. Results were robust to variations in one-way and probabilistic sensitivity analyses.ConclusionsA PHiD-CV 2+1 universal mass vaccination program could substantially reduce pneumococcal disease burden versus no vaccination, and was expected to be cost-effective in Malaysia. A PHiD-CV 2+1 program was also expected to be a dominant choice over a PCV13 2+1 program in Malaysia.Electronic supplementary materialThe online version of this article (doi:10.1186/s12962-017-0079-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 82%

Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia

Wang

Saha²,

Zhang

2017

Cost Eff Resour Alloc

View full text Add to dashboard Cite

show abstract

“…A recent publication by Shiragami et al. (2014) 26 addressed the comparison of PHiD-CV 3+1 and PCV-13 3+1 in the context of a pediatric NIP in Japan over an analytical time horizon of 5 y. The model projected that vaccination with PHiD-CV would result in total cost savings of 16 million or 33 million USD from the provider and societal perspectives, with additional 433 QALYs gained compared with PCV-13.…”

Section: Discussionmentioning

confidence: 99%

“… 25 In Japan, vaccination with PHiD-CV was also estimated to be cost-saving compared with PCV-13, from the healthcare provider and societal perspectives. 26 A review of 15 cost-effectiveness studies on PCV published between 2002 and 2006 found that PCV vaccination could generally be considered attractive in developed countries, although the results varied considerably between studies. 27 Factors contributing to the variation in results included differences in assumptions about vaccine efficacy parameters and disease incidence.…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea

Zhang¹,

Leeuwenkamp²,

et al. 2017

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Background: Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) can cause invasive pneumococcal diseases (IPD), pneumonia, and acute otitis media (AOM). Both the 10-valent pneumococcal NTHi protein D conjugate vaccine (PHiD-CV) and the 13-valent pneumococcal conjugate vaccine (PCV-13) are included in the National Immunization Program for infants in Korea. This study aimed to evaluate the cost-effectiveness of the 3+1 schedule of PHiD-CV versus that of PCV-13 for National Immunization Program in Korea.Methods: A published Markov model was adapted to evaluate the cost-effectiveness of vaccinating the 2012 birth cohort with PHiD-CV vs. PCV-13 from the Korean government perspective over 10 y. Best available published data were used for epidemiology, vaccine efficacy and disutilities. Data on incidence and direct medical costs were taken from the national insurance claims database. Sensitivity analyses were conducted to explore the robustness of the results.Results: PHiD-CV was projected to prevent an additional 195,262 cases of pneumococcal diseases and NTHi-related diseases vs. PCV-13, with a substantially greater reduction in NTHi-related AOM and a comparable reduction in IPD and community-acquired pneumonia. Parity-priced PHiD-CV generated a health gain of about 844 quality-adjusted life years and a total cost-saving of approximately 4 million United States Dollars (USD) over 10 y. 93% of probabilistic simulations found PHiD-CV 3+1 to be the dominant vaccine option.Conclusion: Compared to PCV-13, PHiD-CV was projected to provide similar prevention against IPD and community-acquired pneumonia but would prevent more cases of AOM. Parity-priced PHiD-CV was anticipated to generate substantial cost-savings and health benefits vs. PCV-13 in Korea.

show abstract

“…Instead, previous studies often estimate direct effects for each vaccine based on clinical trial efficacy data, adjusted by local PCV10 or PCV13 serotype coverage [64][65][66][67]. Alternatively, studies estimate the same efficacy for the common vaccine-type serotypes and assume PCV10 provides crossprotection for serotypes 6A and 19A [68][69][70], serotypes only contained in PCV13. However, these approaches are limited by outdated assumptions around serotype replacement and cross protection and create challenges when comparing across economic evaluations because of differences in the literature from which efficacy assumptions are drawn [71,72].…”

Section: Discussionmentioning

confidence: 99%

Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis

et al. 2020

View full text Add to dashboard Cite

Introduction: Widespread use of ten-valent (Synflorix TM , GSK) or 13-valent (Prevenar 13 TM ; Pfizer) conjugate vaccination programs has effectively reduced invasive pneumococcal disease (IPD) globally. However, IPD caused by serotypes not contained within the respective vaccines continues to increase, notably serotypes 3, 6A, and 19A in countries using lower-valent vaccines. Our objective was to estimate the clinical and economic benefit of replacing PCV10 with PCV13 in Colombia, Finland, and The Netherlands. Methods: Country-specific databases, supplemented with published and unpublished data, informed the historical incidence of pneumococcal disease as well as direct and indirect medical costs. A decision-analytic forecasting model was applied, and both costs and outcomes were discounted. The observed invasive pneumococcal disease (IPD) trends from each country were used to forecast the future number of IPD cases given a PCV13 or PCV10 program. Results: Over a 5-year time horizon, a switch to a PCV13 program was estimated to reduce overall IPD among 0-2 year olds by an incremental-37.6% in Colombia,-32.9% in Finland, and-26% in The Netherlands, respectively, over PCV10. Adults [ 65 years experienced a comparable incremental decrease in overall IPD in Colombia (-32.2%), Finland (-15%), and The Netherlands (-3.7%). Serotypes 3, 6A, and 19A drove the incremental decrease in disease for PCV13 over PCV10 in both age groups. A PCV13 program was dominant in Colombia and Finland and cost-effective in The Netherlands at 1 9 GDP per capita (€34,054/QALY). Conclusion: In Colombia, Finland, and The Netherlands, countries with diverse epidemiologic and population distributions, switching from a PCV10 to PCV13 program would Enhanced digital features To view enhanced digital features for this article go to https://doi.org/10.6084/ m9.figshare.11778303.

show abstract

Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children

Cited by 30 publications

References 40 publications

Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia

Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia

Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea

Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis

Contact Info

Product

Resources

About